Qualified and institutional investors as well as advisors and analysts are invited to attend its real-time, interactive presentation at the Emerging Growth Conference June 12.
Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today that it will present at the Emerging Growth Conference on Wednesday, June 12. The company’s presentation, including Q&A, will run from 1:10 pm -1:40 pm Eastern time.
This live, interactive online event will give existing shareholders and the investment community an introduction to the company and an update of recent clinical data highlights and corporate progress. The company’s CFO, Anthony Baldor, will present, with a short Q&A to follow. Questions may be submitted in advance of the event to Questions@EmergingGrowth.com, or during the event through the Emerging Growth Conference presentation platform.
Participants are invited to register at the following link to ensure they will be able to attend the conference and receive any updates that are released: https://goto.webcasts.com/starthere.jsp?ei=1658205&tp_key=76d4029138&sti=diakonos
If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference. A video link will be released after the event.
About the Emerging Growth Conference
The Emerging Growth conference is an effective way for public and private companies to present and communicate key events, progress and other major announcements to the investment community on a convenient and interactive virtual platform, in real time.
The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products and services, focused strategy, execution, and the overall potential for long term growth. Its audience includes tens of thousands of Individual and Institutional investors, as well as investment advisors and analysts.
All sessions will be conducted through video webcasts and will take place in the Eastern time zone.
About Diakonos Oncology Corporation
Based in Houston, TX, Diakonos Oncology is a clinical-stage biotechnology company forging a new frontier in cancer vaccines. We are dedicated to revolutionizing cancer immunotherapy and focusing on difficult-to-treat diseases, including our lead indication, glioblastoma. Additional clinical testing is ongoing in pancreatic ductal adenocarcinoma (PDAC) and other solid tumor indications. For more information visit: www.diakonosoncology.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240610628777/en/
Contacts
Jay Hartenbach
pr@diakonosoncology.com
